SABCS 2022 Conference Coverage


 

SABCS 2022 Results From a Pre-Planned monarchE OS Interim Analysis, Including 4-Year Efficacy Outcomes: Abemaciclib + ET for HR+/HER2-/N+ High-Risk EBC

284 views
January 30, 2023
Comments 0
Login to view comments. Click here to Login